GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GeneReach Biotechnology 4171.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

15.15

+1.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GeneReach Biotechnology

Its shares trade on Taipei Exchange under the ticker 4171.TWO. It has been listed since 19 November 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 232.7m and a net loss of TWD 110.3m. At that date it held total assets of TWD 881.1m and shareholders' equity of TWD 586.7m.

GeneReach Biotechnology Corp. develops, manufactures and markets products for applied nucleic acid detection technology. The company is headquartered in Taichung, Taichung. The company went IPO on 2012-11-19. The firm mainly operates through Taiwan segment. The firm provides shrimp virus testing agents, on-site detection systems for fish and shrimp, mini centrifugal machines, pet disease testing agents and other testing equipment.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
19 Nov 2012
Employees
84

Leadership

Pay as last reported

  • Mr. Leo LiuChairman of the Board, since 2004TWD 6.3m
  • Mr. Simon ChungChief Executive Officer, Director, since 2015TWD 3.2m
  • Ms. Yuyan FuDeputy General Manager - Corporate Support Group, Special Assistant to Chairman of the Board, Director, since 2019
  • Mr. Baihua ChenDeputy General Manager - Research and Development Group
  • Mr. Pinxing ChouSenior Deputy General Manager - Operations
  • Ms. Shuyu CaoHead of Accounting
  • Ms. Xiuying ZhangHead of Finance, Corporate Governance Officer
  • Mr. Conghan LiuDirectorTWD 30,000
  • Huiyu HuangIndependent Director
  • Zhiyao HuangIndependent Director
  • Ms. Zhufang LuoIndependent DirectorTWD 270,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taichung, Taiwan, with a focus on health care sector.
  • Offers specialized products including shrimp virus testing agents and on-site detection systems.
  • Operates primarily through the Taiwan segment with a clear market focus.

Weaknesses

  • Limited to operating primarily through the Taiwan segment, restricting global reach.
  • No mention of international expansion or partnerships in the provided information.
  • Employees count is 84, which may indicate limited operational scale.

Opportunities

  • Potential to expand into international markets for nucleic acid detection technology.
  • Growing demand for health care testing products in global markets.
  • Opportunity to diversify product offerings beyond current testing agents.

Threats

  • Dependence on the Taiwan segment may expose the company to regional economic risks.
  • Competition in the health care testing industry could increase market pressure.
  • Lack of information on regulatory compliance may pose risks in new markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.